Cancer Stem Cells and Stemness: Potential Clinical Implications in Gastrointestinal Cancers

In this CME-certified module, Manish A. Shah, MD, provides his expert perspective on GI cancer stem cells and the promise of cancer stem cell–targeted therapy in the treatment of GI cancers.
Manish A. Shah, MD
Released: January 26, 2017 Expiration: No longer available for credit

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the central role of cancer stem cells in tumorigenesis, relapse, and metastasis of gastrointestinal cancers
  • Evaluate emerging clinical trial data on novel agents targeting cancer stem cells in gastrointestinal cancers

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Boston Biomedical, Inc.

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Chief,
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Manish A. Shaw, MD, has disclosed that he has received funds for research support from Boston Biomedical and Roche.

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with gastrointestinal cancers.

Goal

The goal of this activity is to improve participants’ understanding of cancer stem cells and their potential role in the treatment of patients with gastrointestinal cancers.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2017, through January 25, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this commentary from Clinical Care Options (CCO), experts discuss second-line treatment after atezolizumab plus bevacizumab for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: October 1, 2020

Gain key insights quickly with this short slideset from Clinical Care Options (CCO) on HER2 testing and targeted therapy in advanced GI cancers

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 30, 2020

In this slideset from Clinical Care Options (CCO), experts provide insights on HER2 testing and targeted therapy in advanced gastrointestinal cancers

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 25, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue